Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    A stunning’ 4% yearly rise in R&D share has emerging biopharma dominating the pipeline

    March 31, 2023

    Under pressure, biotech and pharma grapple with how to take climate action

    March 30, 2023

    Antibody-patent row could have far-reaching impact on biotech

    March 29, 2023
    Facebook Twitter Instagram
    Your Biotech
    • Bio Technology

      A stunning’ 4% yearly rise in R&D share has emerging biopharma dominating the pipeline

      March 31, 2023

      Under pressure, biotech and pharma grapple with how to take climate action

      March 30, 2023

      Antibody-patent row could have far-reaching impact on biotech

      March 29, 2023

      Alan Kohler: Australia’s biotech sector has suddenly got much bigger

      March 28, 2023

      Why Do So Few Biotech Startups Want To Be The Next Big Pharma Company?

      March 27, 2023
    • Pharmaceutical

      Pharma company owner duped of ₹1.1 crore

      November 11, 2022

      Novavax cuts full-year revenue forecast again amid weak demand

      November 10, 2022

      Aurobindo units recall products in US market for manufacturing issues

      November 9, 2022

      AASLD 2022 | Ascentage Pharma Releases Phase I Results of IAP Antagonist APG-1387 in an Oral Report Showing Potential for Functionally Curing CHB

      November 8, 2022

      Trade Spotlight | What should you do with Amara Raja, Sun Pharma Advanced Research, Poly Medicure on Monday?

      November 7, 2022
    Your Biotech
    Home»Bio Technology»Pfizer To Acquire Cancer Treatment Biotech Firm Seagen For $43 Billion
    Bio Technology

    Pfizer To Acquire Cancer Treatment Biotech Firm Seagen For $43 Billion

    yourbiotechBy yourbiotechMarch 14, 2023Updated:March 14, 2023No Comments2 Mins Read
    Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp VKontakte Email
    Share
    Facebook Twitter LinkedIn Pinterest Email

    US pharmaceutical giant Pfizer announced Monday that it had reached a deal to buy biotech firm Seagen, specializing in innovative cancer treatment, for $43 billion.
    Pfizer is offering $229 per share in cash, and the companies expect to complete the transaction later this year or in early 2024, they said in a statement.

    “Pfizer is deploying its financial resources to advance the battle against cancer,” said Pfizer CEO Albert Bourla. Oncology continues to be the largest growth driver in global medicine, and this acquisition will enhance Pfizer’s position in this important space,” Bourla added. leading in the research, development, and commercialization of cancer treatments — is growing, with a 12 percent increase in revenue forecast this year to $2.2 billion.

    Targeting Cancer

    The company, headquartered in Washington state, came to major drugmakers’ attention with its work on antibody-drug conjugates (ADCs) that are “designed to preferentially kill cancer cells.”

    The agreement has been approved by the boards of both firms and will be subject to regulatory and shareholder approvals. A deal would have to pass heightened scrutiny from antitrust regulators. The Biden administration has also been seeking to keep down drug prices Pfizer expects to finance the deal through $31 billion of new long-term debt and a “combination of short-term financing and existing cash.”

    For now, Pfizer Oncology has a portfolio of 24 approved innovative cancer medicines that generated $12.1 billion in 2022, it said.

    The deal with Seagen would double Pfizer’s early-stage oncology clinical pipeline, the pharmaceutical firm added. The addition of Seagen’s world-leading ADC technology will position us at the forefront of innovative cancer care,” said Chris Boshoff, Pfizer’s chief development officer of oncology and rare disease.

    Seagen CEO David Epstein added that “the proposed combination with Pfizer is the right next step for Seagen to further its strategy.” According to reports, Pfizer competitor Merck was in talks with Seagen previously but these did not go through. Pfizer expects that Seagen may contribute more than $10 billion in risk-adjusted revenues in 2030, “with potential significant growth beyond 2030,” the company said.

    Seagen’s portfolio includes three products with ADCs, including Padcev, which is used for the treatment of urothelial cancer. PromotedListen to the latest songs, only on JioSaavn.com The US Food and Drug Administration is looking into combining Padcev with Merck’s Keytruda in treating patients with advanced bladder cancer who are not eligible for chemotherapy.

    Share. Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Email
    Previous ArticleSilicon Valley Bank Bet Big On Biotech. And Now It’s Gone.
    Next Article SVB fall casts shadow on early-stage U.S. biotech
    yourbiotech
    • Website

    Related Posts

    A stunning’ 4% yearly rise in R&D share has emerging biopharma dominating the pipeline

    March 31, 2023

    Under pressure, biotech and pharma grapple with how to take climate action

    March 30, 2023

    Antibody-patent row could have far-reaching impact on biotech

    March 29, 2023

    Alan Kohler: Australia’s biotech sector has suddenly got much bigger

    March 28, 2023

    Leave A Reply Cancel Reply

    Our Picks

    Subscribe to Updates

    Get the latest creative news from SmartMag about art & design.

    About Us
    About Us

    We provide a wide range of customized, integrated B2B and B2C digital marketing services solutions that are ideal for your business.

    We're accepting new partnerships right now.

    Email Us: info@yourmartech.com
    Contact: +1-530-518-1420

    Our Brands
    • Your Martech
    • Your HR Tech
    • Your Fin Tech
    • Your Revenue
    • Your Info Tech
    • Your POS Tech
    • Your Health Tech
    SUBSCRIBE NOW
    Loading
    LinkedIn
    • Privacy Policy
    © 2022 Vigarbiz Inc. Designed by Vigarbiz Media

    Type above and press Enter to search. Press Esc to cancel.